BG Medicine Overview
Latest ROE for BG Medicine: 268.32% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow268.32%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for BGMD is 268.32%. That is above the sector sector average of 11.75%. Investors often review this figure alongside BG Medicine's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, BGMD currently prints 268.32% for ROE, while the sector average sits near 11.75%. That is roughly 2182.8% above the sector mean. Large gaps often invite a closer look at BG Medicine's growth, margins, and balance sheet.
Return on Equity shows how effectively BG Medicine converts resources into returns. At 268.32%, BGMD may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting BGMD's ROE (268.32%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
